MedTech Dive October 10, 2024
The funding will support the pivotal trial, premarket approval application and initial commercial launch of a system that could interrupt or change the transmission of pain signals to the brain.
Dive Brief:
- Shiratronics has raised $66 million to fund a pivotal trial of an implantable neuromodulation treatment for chronic migraine, the company said Wednesday.
- The trial is designed to evaluate the safety and effectiveness of the system in patients with treatment-resistant chronic migraine who have failed current medical therapies.
- The Series B funding will also help support the premarket approval process for the device and the initial commercial launch.
Dive Insight:
Researchers have studied occipital nerve stimulation for decades and generated clinical evidence of efficacy against migraine when...
Today's Sponsors
Today's Sponsor